Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Maquart, F.X., Pickart, L., Laurent, M., Gillery, P., Monboisse, J.C
Sci Rep 6:113
SURPASS-4, a multicenter open-label RCT comparing treatment with tirzepatide and insulin glargine in T2D patients at increased CV risk for a median of 85 weeks, was the only study in the SURPASS program to include the change from baseline in eGFR and UACR and occurrence of eGFR decline of at least 40%, renal death, progression to end-stage kidney disease or new-onset MA among the prespecified analyses [48]
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
The program is through the Centers for Medicare & Medicaid Services
US$ 25.83
US$ 26.75
US$ 26.23
US$ 29.43
US$ 27.37
